PLA2R1 and membranous glomerulonephritis: Since the finding of the autoantibody to podocyte antigen PLA2R in membranous nephropathy patients in 2009, accumulating evidences have shown that there was no significant difference in some relevant clinical parameters, such as age, gender, proteinuria or serum creatinine, between PLA2R-associated and non-PLA2R-associated IMN [16, 18], but there is a paucity of data regarding the treatment response between the PLA2R-associated and non-PLA2R-associated IMN.